Regeneron Pharmaceuticals
As on 06 Sep, 2025 | 01:29 IST
| Open | 565.00 |
| Previous Close | 567.22 |
| Beta | -0.10 |
| High | 577.75 |
| Low | 565.15 |
| TTM EPS See historical trend | 45.64(+2.42% YoY) |
| 52 Week High | 1,170.58 |
| 52 Week Low | 476.79 |
| TTM PE See historical trend | 12.56(Low PE) |
| Mkt. Cap ($ Billion) | 62.92 |
| Dividend Yield | 0.34 |
Advanced Chart
*Delayed by 20 seconds.
MC Technicals
| Days | |
|---|---|
| 5 | 572.56 |
| 10 | 577.82 |
| 20 | 574.32 |
| 50 | 559.11 |
| 100 | 558.04 |
| 200 | 632.61 |
Returns
| 1 Week | -2.74% | |
| 1 Month | 2.66% | |
| 3 Months | -5.30% | |
| YTD | -19.53% | |
| 1 Year | -51.40% | |
| 3 Years | -3.30% |
Financialsin million $
Peers
| Name | Price ($) | Change% | M.Cap(Billion $) | TTM PE | TTM EPS | DY | 52 wk high/low | Technical Rating | |
|---|---|---|---|---|---|---|---|---|---|
| Eli Lilly | 727.21 | -2.11 | 691.27 | 45.02 | 16.15 | 0.74 | 941.68/623.99 | -4.78 | Neutral |
| J&J | 178.38 | -0.21 | 429.88 | 17.84 | 10.00 | 2.99 | 181.14/141.30 | 6.17 | Very Bullish |
| AbbVie | 212.56 | -0.21 | 375.50 | 20.07 | 10.59 | 3.49 | 218.58/163.83 | 11.12 | Very Bullish |
| Merck | 84.70 | 0.77 | 214.54 | 11.09 | 7.64 | 4.04 | 120.25/73.35 | 2.37 | Bullish |
| Gilead Sciences | 115.06 | 2.03 | 143.46 | 14.86 | 7.74 | 2.81 | 121.61/78.27 | 0.72 | Bullish |
Market news
- Dow notches record high as Wall Street cheers Powell's speechAugust 23, 2025 10:31 AM
- Dow ends higher after UnitedHealth gains, other indexes slip on rate cut uncertaintyAugust 16, 2025 11:08 AM
- Stocks slump on latest tariffs, soft jobs dataAugust 2, 2025 11:55 AM
- S&P, Nasdaq end on subdued note after brief dip on latest Trump tariff rumblingJuly 19, 2025 9:45 AM
About the company
Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious diseases. The Company commercializes medicines and product candidates for eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases, and rare diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, Kevzara (sarilumab) Solution for Subcutaneous Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion.